Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.
The safety profile of each agent was consistent with those previously reported.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.
Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.
Researchers are comparing the effectiveness of pembrolizumab with that of topotecan among patients with SCLC.
Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.
Non-cigarette tobacco use has increased by over 100% in the last 2 decades.
The FDA based its approval on positive findings from the phase 3 PACIFIC study.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Regular exercise can help patients with cancer deal with issues related to weight gain during treatment.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Researchers are evaluating whether adding a dendritic cell-based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC.
Study findings suggest that some clinicians are using immunotherapies in the types of patients not included in clinical trials.
Management of malignant pleural effusions should be tailored to the particular patient, depending on preference, prognosis, and variety of underlying disease.
Access treatment options for mesothelioma in this detailed drug regimen, which includes agents such as pemetrexed + cisplatin and more.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
Researchers retrospectively analyzed the outcomes of 78 patients with stage IV lung SCC who were treated with gemcitabine plus cisplatin as first-line therapy.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLCDecember 18, 2017
Data from FLAURA may position osimertinib as the first-line standard of care for patients with EGFR-mutant NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy